Authors
Latest:
Exploring the Evolving Treatment Landscape for Advanced Hepatocellular CarcinomaAndrew X. Zhu, MD, PhD, discusses the evolving treatment landscape for patients with hepatocellular carcinoma.
Latest:
Roundtable Discussion: Jakubowiak Looks at New Agents for Relapsed/Refractory Multiple MyelomaDuring a Targeted Oncology Case-Base Roundtable event, Andrzej Jakubowiak, MD, PhD, led a discussion on new agents for the treatment of multiple myeloma.
Latest:
Ongoing Clinical Trials in TNBCAnees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses ongoing clinical trials in the field of triple-negative breast cancer (TNBC).
Latest:
Dr. Chagpar on Contralateral Prophylactic MastectomyAnees B. Chagpar, MD, MPH, MBA, Yale Comprehensive Cancer Center, discusses contralateral prophylactic mastectomy for patients with breast cancer.
Latest:
Treatment Type and Cognitive Impairment in GISTDuring the 2018 Annual Meeting of the Connective Tissue Oncology Society, Anette Duensing, MD, assistant professor of pathology at University of Pittsburgh, discusses the need for further investigation into how treatment type impacts perceived cognitive function in patients with gastrointestinal stromal tumor.
Latest:
The Role of DNA Repair in Triple Negative Breast CancerAngela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses the biology of triple negative breast cancer and the significant role of DNA repair.
Latest:
Analyzing Predictors of Response to Neoadjuvant Chemotherapy in Breast CancerAngela DeMichele, MD, MSCE, discusses predictors of response to neoadjuvant chemotherapy in various subgroups of patients with breast cancer. Selecting characteristics of patients who will most likely benefit from this therapy is not an exact science, she adds.
Latest:
An Analysis of the PANORAMA 1 TrialAngela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses the results of the PANORAMA 1 trial: a randomized, double-blind, phase III study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.
Latest:
Mirvetuximab Soravtansine: Delivering Powerful Results in Ovarian CancerAngeles Alvarez Secord, MD, MHSc, discusses key takeaways from the PICCOLO trial.
Latest:
Expert Discusses Real-World Data for Regorafenib in mCRCReal-world dosing data for regorafenib in patients with metastatic colorectal cancer was presented at the 2018 ESMO Congress from the prospective, observational CORRELATE study.
Latest:
ADCs Stake Their Claim in Lymphoma ParadigmAntibody–drug conjugate therapies are making a larger impact on the treatment paradigm for patients with lymphomas, especially following promising data for brentuximab vedotin and inotuzumab ozogamicin.
Latest:
Breast Ultrasound Added to Mammography Increases Cancer DetectionMore breast cancer lesions were diagnosed in women with dense breasts when ultrasound screening was conducted in conjunction with mammography compared with mammography alone.
Latest:
The Role of Stereotactic Radiosurgery in the Treatment of Brain MetastasesAnita Mahajan, MD, professor, The University of Texas MD Anderson Cancer Center, discusses a recent study into the role of stereotactic radiosurgery in treating brain metastases.
Latest:
First-In-Human Trial Shows Responses With Off-the-Shelf CAR T-Cell Therapy in MyelomaThe off-the-shelf CAR T-cell therapy ALLO-715, which targets BCMA, demonstrated responses as treatment of patients with heavily pretreated relapsed/refractory multiple myeloma in a first-in-human clinical trial.
Latest:
Durable Complete Remissions Achieved in NHL Following CAR TComplete remissions were achieved in greater than 20% of patients with highly refractory non-Hodgkin lymphomas who had been previously been treated with chimeric antigen receptor T-cell therapy with Mosunetuzumab, a novel bispecific antibody, according to study results presented at the 2019 American Society of Hematology Annual Meeting.
Latest:
CASPIAN Update Shows Ongoing Survival Benefit With Durvalumab in ES-SCLC“Importantly, the separation among the curves seems to be observed over time and, indeed, survival at 2 years improves from 14% [of participants] in the control arm to 22% on the experimental arm. The magnitude of the benefit is very similar and very consistent across all the prespecified subgroups of patients analyzed, including those treated with cisplatin or those patients with liver or brain metastases.”
Latest:
Findings of a Study Comparing Standard Radiation to IMRT in Endometrial, Cervical CancerAnn H. Klopp, MD, PhD, discusses the results of a recent trial comparing standard radiation to intensity-modulated radiation therapy (IMRT) in endometrial and cervical cancer, and what impact these results will have.
Latest:
Moving Forward From Monotherapy in HCCAnn-Lii Cheng, MD, discusses where the of hepatocellular carcinoma is headed.
Latest:
Dr. Ann Partridge on Aggressive Breast Cancer in Younger WomenPartridge says that the current school of thought is younger women should be treated the same as older women with breast cancer, though younger women tend to develop more aggressive breast cancer with more nodal involvement.
Latest:
Dr. Ann Partridge on Epidemic of Bilateral Mastectomies in Breast CancerPartridge says there continues to be a growing epidemic of women getting a bilateral mastectomy for unilateral breast cancer. These surgeries include women who are not at high-risk.
Latest:
LaCasce on Bispecific Antibodies Transforming Lymphoma CareAnn LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.
Latest:
Preliminary Results of Coxsackievirus With Pembrolizumab In Advanced MelanomaAnn W. Silk, MD, discusses preliminary results of the CAPRA trial, a phase 1B study of intratumoral coxsackievirus A21 (CVA21; CAVATAK) and systemic pembrolizumab in patients with advanced melanoma.
Latest:
Androgen-Targeting Therapies Increasing in CRPCA new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the treatment of CRPC.
Latest:
Dr. Pavlick on the Importance of Tumor Biopsies in MelanomaAnna C. Pavlick, DO, co-director, Melanoma Program, assistant director, Clinical Research Education, associate professor, Departments of Medicine and Dermatology, Langone Medical Center, New York University, discusses the benefits of biopsying melanoma tissue before treatment to better target therapy.
Latest:
Ipilimumab Combined With Nivolumab for the Treatment of Patients With MelanomaAnna C. Pavlick, MD, associate professor, co-director, Melanoma Program, assistant director, Clinical Research Education, discusses a study that examined two immunotherapy agents, ipilimumab and nivolumab, in patients with melanoma.
Latest:
Challenges in Treating Small Cell Lung CancerAnna Farago, MD, PhD, assistant, medicine, Massachusetts General Hospital, discusses challenges in treating small cell lung cancer.
Latest:
A Study of Brentuximab Vedotin Plus AVD in Hodgkin LymphomaAnna Sureda, MD, PhD, Head of the Clinical Hematology Service at the Institut Català d'Oncologia – Hospitalet de Llobregat in Barcelona, discusses the phase III ECHELON-1 study exploring brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma.
Latest:
Managing PD-L1-Positive NSCLC in the Long-TermAnne Chiang, MD, PhD, discusses the takeaways from her presentation given at the 18th Annual New York Lung Cancers Symposium.
Latest:
Dr. Anne Covey on Locoregional Therapy in Hepatocellular CarcinomaAnne Covey, MD, discusses options for patients with hepatocellular carcinoma (HCC) who cannot undergo resection or transplant.
